Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Rhabdoid Tumor 1Neoplasms 1Colorectal Neoplasms 1Chordoma 1Carcinoma, Squamous Cell 1Carcinoma, Renal Cell 1Advanced Liver Cancers 1

Interventions

pembrolizumab 20Bevacizumab 14Carboplatin 12Standard of Care 10Nivolumab 9Cyclophosphamide 9Cetuximab 8Pemetrexed 7Exercise 7Doxorubicin 7durvalumab 6atezolizumab 6Temozolomide 6Radiotherapy 6Prednisone 6Paclitaxel 6Cisplatin 6Blood Specimen Collection 6abemaciclib 5Fluorouracil 5130-nm albumin-bound paclitaxel 5olaparib 4dostarlimab 4Rituximab 4Leucovorin 4Gemcitabine 4Fulvestrant 4Docetaxel 4Dexamethasone 4venetoclax 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × Tiragolumab × 30 days × Clear all
NCT05862285 2026-05-12

UmbrellaMAX

Hoffmann-La Roche

Phase 3 Recruiting
100 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡